DasPAQT: Treating patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib: PCR-Monitoring, adherence, quality of life, therapy satisfaction (OMC 2014-I; BMS CA180-565) - an analysis of the first 150 patients

Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, Belleville E, Schardt C, Azeh , Steinmetz T (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 39

Pages Range: 57-57

Involved external institutions

CORRECTIV – Recherchen für die Gesellschaft gemeinnützige GmbH DE Germany (DE) Onko.LogiẊ GmbH & Co.KG. DE Germany (DE) MVZ Onkologie GmbH DE Germany (DE) ClinSol GmbH & Co.KG DE Germany (DE) Ambulantes Therapiezentrum für Hämatologie und Onkologie DE Germany (DE)

How to cite

APA:

Tesch, H., Pelz, H., Janssen, J., Hansen, R., Fietz, T., Anhuf, J.,... Steinmetz, T. (2016). DasPAQT: Treating patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib: PCR-Monitoring, adherence, quality of life, therapy satisfaction (OMC 2014-I; BMS CA180-565) - an analysis of the first 150 patients. (pp. 57-57).

MLA:

Tesch, H., et al. "DasPAQT: Treating patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib: PCR-Monitoring, adherence, quality of life, therapy satisfaction (OMC 2014-I; BMS CA180-565) - an analysis of the first 150 patients." 2016. 57-57.

BibTeX: Download